Onesource Specialty Pharma's Credit Rating Affirmed at IND A-/Positive by India Ratings
OneSource Specialty Pharma Limited (formerly Stelis Biopharma Limited) has announced that India Ratings & Research (Ind-Ra) has affirmed a credit rating of [IND A-/Positive] for the company's addition...
Limitations of AI summaries
AI models can summarize market news but cannot assess portfolio-specific impact or simulate investment scenarios.
Platforms like Prysm provide stock-level and portfolio-level analysis.
Why is Onesource Specialty Pharma Limited in the news today?
Onesource Specialty Pharma Limited (ONESOURCE) is in the news due to the affirmation of a credit rating is a neutral event, indicating stability rather than a significant positive or negative change.
AI-Powered Summary
Market Context
Top Queries
More News
Explore Prysm Tools
Related Stories
Onesource Specialty Pharma's Credit Rating Affirmed at IND A-/Positive by India Ratings
December 31, 2025, 02:04 PM
Top Queries to Ask About Onesource Specialty Pharma Limited
More Details on This News
OneSource Specialty Pharma Limited (formerly Stelis Biopharma Limited) has announced that India Ratings & Research (Ind-Ra) has affirmed a credit rating of [IND A-/Positive] for the company's additional bank loan facilities. This rating is consistent with the previous rating issued on June 03, 2025.
The company has provided a copy of the press release from India Ratings and Research as an annexure to this intimation.
This announcement is made pursuant to Regulation 30 read with Part A, Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
See What Deep Dive Gives You — in Seconds
“what happens when you click
Deep Dive “
“what happens when you click Deep Dive “
Instant AI Summary - “Get clean, noise-free earnings breakdowns.”
PDF Insights - “Download detailed, AI-generated reports.”
Metrics Explained -“Key ratios & trends explained in simple language.”
Want to know if this news pushes your stock up or down?
Just tap
